London, England -- (SBWIRE) -- 03/21/2012 -- GlobalData estimates that the global Multiple Sclerosis (MS) therapeutics market was valued at $9,237m in 2011. The global MS therapeutics, which includes Disease Modifying Drugs (DMDs) and drugs for symptom management, is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.2% over the next eight years, to reach $11,914m by 2019. The rapid growth of the market during 2006-2011 (13.6% CAGR) was mainly due to the growth in diagnosed and treated patients. The treated patient pool registered rapid growth due to the introduction of new diagnostic criteria called the McDonald criteria, which integrated MRI findings into clinical assessments and resulted in a greater number of confirmed MS diagnoses. In addition, the understanding of the disease’s pathogenesis has improved.

The current MS therapeutics market includes DMDs approved for the management of Relapse-Remitting MS (RRMS) and drugs for symptom management. At present there are no approved drugs for the progressive stages of the disease. The DMDs prescribed for MS include four interferons: Avonex, Betaseron, Extavia and Rebif. Betaseron (US) is available as Betaferon in Europe and Japan. Other DMDs include Copaxone, Tysabri, Ampyra and Gilenya (recently launched). Gilenya is the first oral drug introduced in the market. The RRMS patients account for approximately 45% of the total MS patients. The drugs for symptom management include antidepressants, spasmolytics along with drugs for managing pain, fatigue, inflammation and so on. In the absence of any approved drugs for the progressive stages of the disease, the drugs for symptom management are prescribed.

The MS therapeutics market is expected to witness slow growth (in terms of CAGR) through the forecast period to 2019 in comparison with the historical period 2006-2011. In 2011, the US accounted for more than half of the global MS therapeutics market. The slow growth in the market is the result of the cumulative effect of both positive and negative factors within the market. The patent expiry of Copaxone (expected US patent expiry 2014 and expected European patent expiry 2015) is expected to negatively impact the US market; Copaxone has a high cost of therapy and has a strong presence in the US market. However, the introduction of pipeline products will neutralize the value erosion of the market, resulting in slow growth through to 2019. Aubagio (teriflunamide), Dimethyl Fumarate (BG-12), Daclizumab, RG1594 (ocrelizumab) and Lamtrada (alemtuzumab) are the novel late stage pipeline products likely to enter the market through to 2019.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Multiple-Sclerosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&companyID=sbwire

The launch of new pipeline products is expected to change the present market scenario, which is mainly dependant on injectable formulations (such as Avonex, Betaseron/Betaferon, Rebif, Copaxone, and Tysabri). These drugs need to be injected frequently, and their dose frequency ranges from daily to weekly administration. Within the new drugs some are oral formulations (Aubagio and BG-12) and some are injectable formulations (daclizumab, ocrelizumab and alemtuzumab) and all require dosing either once a month or once every six months.

GlobalData, the industry analysis specialist, has released its new report, “Multiple sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global multiple sclerosis therapeutics market. The report identifies the key trends shaping and driving the global market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global multiple sclerosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Multiple-Sclerosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782